Items Tagged ‘Renal Cancer’

April 23, 2018

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer

By

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than […]

View full entry

Tags: atezolizumab, Checkpoint inhibitors Keytruda, durvalumab, Imfinzi, kidney cancer, News, nivolumab, opdivo, pembrolizumab, Renal Cancer, renal cell cancer, Tecentriq


January 25, 2018

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: immunotherapy, keytruda, lenvatinib, Lenvima, News, pembrolizumab, Precision Cancer Medicine, Renal Cancer, renal cell cancer


January 5, 2018

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma

By

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy.  The FDA previously approved Cabometyx in 2016 for treatment of […]

View full entry

Tags: Cabometyx, cabozantinib, kidney cancer, News, Renal Cancer, renal cell carcinoma, Sutent


November 9, 2017

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

By

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each […]

View full entry

Tags: afinitor, checkpoint inhibitor, everolimus, immunotherapy, metastatic kidney cancer, News, opdivo, PD-1, Precision Cancer Medicine, Renal Cancer


March 31, 2009

Nexavar® Is Better Tolerated than Interferon in Patients with Metastatic Renal Cell Carcinoma

By

In patients with untreated renal cell cancer (RCC), Nexavar® (sorafenib) results in a similar progression-free survival (PFS) to interferon, yet patients experience greater rates of tumor shrinkage and report a better quality of life (QOL) with Nexavar than with interferon. The results of this study were published in the Journal of Clinical Oncology.1  The kidneys are […]

View full entry

Tags: Renal Cancer